Morales-Hernández Sergio, Ugidos-Damboriena Nerea, López-Sagaseta Jacinto
Unit of Protein Crystallography and Structural Immunology, Navarrabiomed-Public University of Navarra (UPNA), 31008 Pamplona, Spain.
Navarra University Hospital, 31008 Pamplona, Spain.
Vaccines (Basel). 2022 Sep 2;10(9):1447. doi: 10.3390/vaccines10091447.
Vaccines constitute a pillar in the prevention of infectious diseases. The unprecedented emergence of novel immunization strategies due to the COVID-19 pandemic has again positioned vaccination as a pivotal measure to protect humankind and reduce the clinical impact and socioeconomic burden worldwide. Vaccination pursues the ultimate goal of eliciting a protective response in immunized individuals. To achieve this, immunogens must be efficiently delivered to prime the immune system and produce robust protection. Given their safety, immunogenicity, and flexibility to display varied and native epitopes, self-assembling protein nanoparticles represent one of the most promising immunogen delivery platforms. Currently marketed vaccines against the human papillomavirus, for instance, illustrate the potential of these nanoassemblies. This review is intended to provide novelties, since 2015, on the ground of vaccine design and self-assembling protein nanoparticles, as well as a comparison with the current emergence of mRNA-based vaccines.
疫苗是预防传染病的一大支柱。由于新冠疫情而出现的前所未有的新型免疫策略,再次将疫苗接种定位为保护人类、减少全球临床影响和社会经济负担的关键措施。疫苗接种追求在接种个体中引发保护性反应这一最终目标。为实现这一目标,免疫原必须被有效地递送,以启动免疫系统并产生强大的保护作用。鉴于其安全性、免疫原性以及展示各种天然表位的灵活性,自组装蛋白纳米颗粒是最有前景的免疫原递送平台之一。例如,目前市场上销售的针对人乳头瘤病毒的疫苗就展示了这些纳米组装体的潜力。本综述旨在介绍自2015年以来在疫苗设计和自组装蛋白纳米颗粒方面的新进展,以及与当前出现的基于mRNA的疫苗进行比较。